Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.
The effects of long-term interferon- beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
The role of T cell apoptosis in nervous system autoimmunity.
Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing-Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate.
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
[The Sjögren's syndrome and multiple sclerosis: similarity and differences.]
Ustekinumab.
Changes to anti-JCV antibody levels in a Swedish national MS cohort.
The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.
Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
Company restores access to multiple sclerosis drug after pressure from neurologists.
The potential role of epigenetic modifications in the heritability of multiple sclerosis.
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
Cognitive impairment and cortical degeneration in neuromyelitis optica.
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Roche reports positive studies of MabThera given by subcutaneous injection
[Nicolau syndrome after administration of glatiramer acetate].
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
GEMSP: A New Therapeutic Approach to Multiple Sclerosis.
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.

Pages